• Visionflex signs binding agreement with Amplar Health to supply virtual care technology
• Project to include up to 30 Residential Aged Care Homes across Australia
• Potential Total Contract Value of approximately $1.0 million

Visionflex Group Limited (ASX:VFX), a leader in virtual diagnostic healthcare technology solutions, has announced its strategic partnership with Amplar Health -- Medibank's health service delivery company. This collaboration is designed to ensure older Australians receive consistent, timely care when and where they need it. The project will run from March 2025 until June 2027 and will focus on enhancing care delivery in rural and remote areas, as well as in facilities supporting older people of First Nations and culturally and linguistically diverse backgrounds. Under the terms of the agreement, Visionflex will provide its comprehensive virtual care solution--integrating its hardware and software platform -- to the participating Residential Aged Care Homes (RACHs). The agreement is structured to include approximately $750,000 in one-off hardware revenue and approximately $250,000 in software subscription revenue over the trial period to June 2027, subject to Amplar Health's full roll-out across up to 30 RACHs. Deployment will occur on a phased basis over the next 15 months to ensure optimal configuration and seamless integration. The project will explore how virtual nursing services can be integrated into aged care homes to provide critical support to on-site staff and ensure that residents are able to access personalised clinical care. While virtual nursing care is not intended to replace face-to-face services, it aims to extend clinical expertise to homes in need, improving care continuity for residents. If successful, the project is expected to provide a scalable model for augmenting on-site care through virtual nursing.

The potential Total Contract Value (TCV) of approximately $1.0 million -- comprising approx. $750,000 in one-off hardware revenue and approx. $250,000 in software subscription revenue over the trial period to June 2027 -- subject to Amplar Health's full roll-out.